By using the well-established P53 deficiency mouse models (heterozygous and homozygous Tp53 deletion), we sought to not only further establish the mechanism of PTEN regulation by PRL2 but also assess the therapeutic potential of PRL2 inhibition for PTEN augmentation therapy in the treatment of cancers that develop without PTEN alteration. The gene discussed is PTP4A2; the disease is cancer.